Related Experiment Videos
Human uveal melanoma expresses NG2 immunoreactivity
Y Li1, M C Madigan, K Lai
1Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray Street, Kogarah, NSW, Australia.
The British Journal of Ophthalmology
|April 26, 2003
Summary
Most human uveal melanomas express NG2, detected by monoclonal antibody 9.2.27. This finding suggests NG2 as a potential target for radioimmunotherapy in ocular melanoma treatment.
Area of Science:
- Ophthalmology
- Oncology
- Immunohistochemistry
Background:
- NG2 proteoglycan is expressed in various cancers, including cutaneous melanoma.
- Monoclonal antibody (mAb) 9.2.27 recognizes NG2 and has been explored for melanoma targeting.
- Uveal melanoma is a rare but aggressive eye cancer.
Purpose of the Study:
- To evaluate NG2 immunoreactivity in human uveal melanoma.
- To assess NG2 expression in normal ocular tissues for comparison.
- To determine the suitability of mAb 9.2.27 for targeting uveal melanoma.
Main Methods:
- Paraffin-embedded uveal melanoma tissues (n=26) and normal ocular tissues (n=5) were analyzed.
- Immunohistochemistry using mAb 9.2.27 and APAAP staining was performed.
- Immunostaining was graded semi-quantitatively by two independent observers.
Main Results:
- NG2 immunoreactivity was detected in 95% (18/19) of evaluable uveal melanomas.
- Pigmentation interfered with grading in 7 cases.
- Normal ocular tissues showed weak to negative NG2 staining, while optic nerve axon bundles showed moderate staining.
Conclusions:
- The majority of human uveal melanomas express NG2.
- mAb 9.2.27 is a potential tool for targeting uveal melanoma.
- NG2-targeted radioimmunotherapy may be a viable treatment option for ocular melanoma.